GR3020984T3 - Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori. - Google Patents

Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori.

Info

Publication number
GR3020984T3
GR3020984T3 GR960402279T GR960402279T GR3020984T3 GR 3020984 T3 GR3020984 T3 GR 3020984T3 GR 960402279 T GR960402279 T GR 960402279T GR 960402279 T GR960402279 T GR 960402279T GR 3020984 T3 GR3020984 T3 GR 3020984T3
Authority
GR
Greece
Prior art keywords
rifaximin
pharmaceutical compositions
compositions containing
helicobacter pylori
treatment
Prior art date
Application number
GR960402279T
Other languages
English (en)
Inventor
Antonella Ferrieri
Leone Gabriele Rotini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of GR3020984T3 publication Critical patent/GR3020984T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GR960402279T 1993-03-23 1996-09-12 Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori. GR3020984T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93BO000099A IT1264494B1 (it) 1993-03-23 1993-03-23 Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Publications (1)

Publication Number Publication Date
GR3020984T3 true GR3020984T3 (en) 1996-12-31

Family

ID=11338806

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960402279T GR3020984T3 (en) 1993-03-23 1996-09-12 Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori.

Country Status (11)

Country Link
US (1) US5352679A (el)
EP (1) EP0616808B1 (el)
JP (1) JP2755550B2 (el)
KR (1) KR0177846B1 (el)
AT (1) ATE142495T1 (el)
CA (1) CA2115381C (el)
DE (1) DE69400493T2 (el)
DK (1) DK0616808T3 (el)
ES (1) ES2091649T3 (el)
GR (1) GR3020984T3 (el)
IT (1) IT1264494B1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
WO1996024341A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
TW534813B (en) * 1997-02-28 2003-06-01 Kaneka Corp Treating agent for diseases due to infection with helicobacter
AU2002360416A1 (en) * 2001-11-21 2003-06-10 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
EP2837378A1 (en) † 2007-07-06 2015-02-18 Lupin Limited Pharmaceutical compositions of rifaximin
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
PL3628319T3 (pl) 2008-10-02 2024-04-29 Salix Pharmaceuticals, Ltd. Leczenie encefalopatii wątrobowej za pomocą ryfaksyminy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
RU2012126080A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Местная пенообразующая композиция
JP2013511570A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US20130315988A1 (en) 2010-09-13 2013-11-28 Cipla Limited Pharmaceutical Composition
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
SI3546464T1 (sl) 2014-05-12 2020-09-30 Alfasigma S.P.A. Priprava in uporaba rifaksimina v kristalni obliki TAU solvatiranega z degme
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
CN110087688B (zh) 2016-10-14 2023-05-05 希普拉有限公司 包含利福昔明的药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Also Published As

Publication number Publication date
DK0616808T3 (da) 1996-09-30
IT1264494B1 (it) 1996-09-24
ATE142495T1 (de) 1996-09-15
JPH06298768A (ja) 1994-10-25
JP2755550B2 (ja) 1998-05-20
US5352679A (en) 1994-10-04
ITBO930099A1 (it) 1994-09-23
ITBO930099A0 (it) 1993-03-23
KR0177846B1 (ko) 1999-03-20
CA2115381A1 (en) 1994-09-24
EP0616808A1 (en) 1994-09-28
EP0616808B1 (en) 1996-09-11
CA2115381C (en) 1999-01-05
DE69400493T2 (de) 1997-01-23
ES2091649T3 (es) 1996-11-01
DE69400493D1 (de) 1996-10-17

Similar Documents

Publication Publication Date Title
GR3020984T3 (en) Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori.
UA32525C2 (uk) Стійка до шлункового соку форма лікарського засобу на основі пантопразолу для орального введення
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
PL304389A1 (en) Pharmaceutical composition for controllable release
CA2348086A1 (en) Controlled-release pharmaceutical formulations
HU9700589D0 (en) Extended release formulation
AU645555B2 (en) Improvements in or relating to the treatment of gastrointestinal disorders
BG104727A (en) Pharmaceutical composition of topiramate
CA2108455A1 (en) Pharmaceutical compositions against gastric disorders
CA2315408A1 (en) A double capsule for the administration of active principles in multiple therapies
IL96995A0 (en) Pharmaceutical compositions containing pimobendan and their preparation
WO1992018111A3 (en) Pharmaceutical composition for the treatment of gastritis
AU638083B2 (en) Swallowable dosage units comprising colloidal bismuth subcitrate
SG40063A1 (en) Concomitant treatment with oral-topical dosage forms of bismuth compounds antibacterials/antibiotics to eradicate H.pylori from the oral cavity in combination
IL86077A0 (en) Receptor of the small rhinovirus receptor group,its preparation and pharmaceutical compositions containing it
EP0515995A3 (en) N-(5-thioxo-l-prolyl)-l-cysteine, derivatives thereof, processes for the preparation thereof and pharmaceutical compositions containing them
GR3007110T3 (el)
CA2518738A1 (en) Method and composition for preventing or reducing diarrhea
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
EP0268868A3 (en) Pharmaceutical compositions for the treatment of gastro-intestinal diseases
EP1707568A3 (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
GB2314507A (en) Anti-emetic pharmaceutical compositions containing methotrimeprazine
AU5733596A (en) Compositions containing bismuth, for the treatment and preve ntion of gastrointestinal disorders
EP1683515A3 (en) Bismuth-containing compounds in topical dosage forms